Perrigo Q3 net sales miss estimates

Perrigo

05/11/2025 11:44

Overview

Perrigo Q3 2025 net sales down 4.1%, missing analyst expectations

Adjusted EPS for Q3 2025 beats analyst estimates

Company updates FY 2025 outlook due to industry dynamics and market trends

Outlook

Perrigo revises 2025 outlook due to infant formula dynamics and soft OTC trends

Company expects 2025 adjusted EPS of $2.70 to $2.80, up 5% to 9%

Perrigo forecasts 2025 net sales growth of -2.5% to -3.0%

Result Drivers

OTC MARKET SHARE GAINS - Perrigo achieved dollar, unit, and volume share gains in five of seven OTC store brand categories despite soft market consumption trends

STRATEGIC BUSINESS REVIEWS - Ongoing strategic reviews of Infant Formula and Oral Care businesses, with a focus on portfolio evaluation

CURRENCY AND COST MANAGEMENT - Favorable currency translation and disciplined cost management partially offset declines in adjusted operating income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Miss
$1.04 bln
$1.09 bln (3 Analysts)
Q3 Adjusted EPS
Beat
$0.80
$0.75 (3 Analysts)
Q3 EPS
$0.09
Q3 Adjusted Operating Income
Beat
$173 mln
$168.60 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Perrigo Company PLC is $32.00, about 36.9% above its November 4 closing price of $20.19

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn6XplXha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)